| Literature DB >> 25598971 |
Jon Birger Haug1, Dag Berild1, Mette Walberg2, Åsmund Reikvam3.
Abstract
BACKGROUND: Surveillance data of antibiotic use are increasingly being used for benchmarking purposes, but there is a lack of studies dealing with how hospital- and patient-related factors affect antibiotic utilization in hospitals. Our objective was to identify factors that may contribute to differences in antibiotic use.Entities:
Keywords: Antibiotic surveillance; Antibiotic use; Hospitals; Risk factors
Year: 2014 PMID: 25598971 PMCID: PMC4296539 DOI: 10.1186/s13756-014-0040-5
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Measurement units and value ranges for continuous variables entered into 12 linear regression models
|
|
|
|
|
|---|---|---|---|
| Hospital stay < 2 days | % of discharges | 24.5–40.5 | 32.4 |
| Hospital stay > 10 days | % of discharges | 5.2–17.3 | 9.7 |
| Number of physiciansb | per 100 hospital beds | 38.8–128.3 | 63.9 |
| Number of nurses | per 100 hospital beds | 132.5–300.1 | 197.6 |
| IDc main ICD-10 diagnosis | % of discharges | 1.6–6.0 | 2.9 |
| Cancer main ICD-10 diagnosisb | % of discharges | 3.6–17.1 | 8.0 |
| Surgical DRGs | % of discharges | 18.0–39.8 | 27.5 |
| Medical DRGsb | % of discharges | 46.4–79.6 | 65.9 |
| All ambulatory consultationsb | per 100 hospital beds | 89.9–543.3 | 327.6 |
| IDc ambulatory consultationsd | per 100 hospital beds | 0.5–7.7 | 2.7 |
| Day-care treatmentsd | per 100 hospital beds | 10.1–79.5 | 35.9 |
a132 data points: six years of 22 Health Enterprise's annual data.
bVariable removed from the regression models due to collinearity.
cID: (any) infectious diseases.
dVariable included in model, but not significantly associated with antibiotic use.
Description of three categorical variables entered into 12 linear regression models
|
|
|
|
|
|
|---|---|---|---|---|
| University HEsb (30) | 40.6 | 40.7 | 38.5 | 4.9 |
| Non-university HEs (102) | 59.4 | 59.3 | 61.5 | 4.5 |
| Health Region 1 (60) | 54.0 | 54.2 | 55.5 | 4.5 |
| Health Region 2 (30) | 20.3 | 20.8 | 20.5 | 4.7 |
| Health Region 3 (18) | 14.3 | 14.5 | 13.8 | 4.8 |
| Health Region 4 (24) | 11.4 | 10.4 | 10.2 | 4.7 |
| HEs < 300 beds (35) | 9.0 | 8.6 | 8.3 | 4.8 |
| HEs 300–600 beds (50) | 31.0 | 31.7 | 33.3 | 4.4 |
| HEs > 600 beds (47) | 60.0 | 59.7 | 58.5 | 4.7 |
132 data points (22 HEsb over 6 years) for each independent variable.
aOf the three categorical variables, only university affiliation was independently associated with antibiotic use in eight of the 12 regression models.
bHE = Health Enterprise.
Figure 1All antibiotic and broad-spectrum antibiotic use in 22 Norwegian Health Enterprises (HEs), 2006 – 2011. Annual utilization averages for all HEs and according to university affiliation of HEs.
Explanatory factors significantly related to antibiotic use (number of bed days as denominator) in Norwegian Health Enterprises, 2006–2011, derived from six multiple linear regression models
|
|
|
| ||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
| ||||||
| Regression coeff. (95% C.I.) | 5.35*** (2.33; 8.38) | 3.83*** (1.34; 6.33) | 2.86** (1.00; 4.71) | 1.56** (0.59; 2.54) | ||
| Beta weight | 0.47 | 0.45 | 0.41 | 0.44 | ||
| Increment in R2 | 0.0690 | 0.0633 | 0.0509 | 0.0606 | ||
|
| ||||||
| Regression coeff. (95% C.I.) | 0.17*** (0.08; 0.26) | 0.10*** (0.04; 0.15) | 0.10** (0.04; 0.17) | 0.02* (0.001; 0.04) | 0.04** (0.02; 0.06) | |
| Beta weight | 0.56 | 0.44 | 0.57 | 0.28 | 0.39 | |
| Increment in R2 | 0.1141 | 0.0706 | 0.1163 | 0.0293 | 0.0548 | |
|
| ||||||
| Regression coeff. (95% confidence interval (C.I.)) | 0.81* (0.04; 1.57) | 0.31* (0.05; 0.58) | 0.29* (0.04; 0.53) | |||
| Beta weight | 0.29 | 0.38 | 0.40 | |||
| Increment in R2 | 0.0422 | 0.0718 | 0.0829 | |||
|
| ||||||
| Regression coeff. (95% C.I.) | −11.82** (−20.5; −3.2) | −2.65*** (−4.01; −1.29) | −8.22*** (−12.3; −4.1) | −2.72*** (−3.53; −1.91) | ||
| Beta weight | −0.55 | −0.41 | −0.62 | −0.49 | ||
| Increment in R2 | 0.1078 | 0.0607 | 0.1354 | 0.0868 | ||
|
| ||||||
| Regression coeff. (95% C.I.) | 0.15* (0.01; 0.30) | 0.52* (0.06; 0.97) | ||||
| Beta weight | 0.29 | 0.48 | ||||
| Increment in R2 | 0.0222 | 0.0589 | ||||
Significance levels: *P < 0.05, **P < 0.01, ***P < 0.001.
aBroad-spectrum antibiotics: second- and third-generation cephalosporins, fluoroquinolones, carbapenems, and penicillins with enzyme inhibitors.
bAll penicillins: penicillinase sensitive, penicillinase resistant and extended-spectrum penicillins.
cDRG: Diagnosis-related groups.
Explanatory factors related to antibiotic use (number of discharges as denominator) in 22 Norwegian Health Enterprises, 2006–2011, derived from six multiple linear regression models
|
|
|
| ||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
| ||||||
| Regression coeff. (95% confidence interval (C.I.)) | 30.6*** (15.9; 45.2) | 21.9*** (10.0; 33.8) | 16.4*** (7.5; 25.4) | 8.95*** (4.3; 13.6) | ||
| Beta weight | 0.44 | 0.45 | 0.36 | 0.44 | ||
| Increment in R2 | 0.0588 | 0.0614 | 0.0406 | 0.0591 | ||
|
| ||||||
| Regression coeff. (95% C.I.) | 0.78*** (0.37; 1.20) | 0.46*** (0.21; 0.72) | 0.49*** (0.21; 0.77) | 0.17** (0.07; 0.27) | ||
| Beta weight | 0.43 | 0.36 | 0.42 | 0.43 | ||
| Increment in R2 | 0.0657 | 0.0463 | 0.0625 | 0.0357 | ||
|
| ||||||
| Regression coeff. (95% (C.I.) | 12.1** (5.1; 19.2) | 2.38** (0.9; 3.86) | 7.46* (1.2; 13.7) | 8.27*** (4.4; 12.2) | 2.75** (1.2; 4.3) | 2.99*** (0.4; 5.6) |
| Beta weight | 0.48 | 0.45 | 0.42 | 0.51 | 0.56 | 0.41 |
| Increment in R2 | 0.0861 | 0.0753 | 0.0663 | 0.0956 | 0.1157 | 0.0616 |
|
| ||||||
| Regression coeff. (95% C.I.) | −47.6*** (−84.6; −10.7) | −9.8** (−15.5; −4.1) | −33.6*** (−51.1; −16.2) | −10.9*** (−14.5; −7.2) | ||
| Beta weight | −0.36 | −0.35 | −0.39 | −0.42 | ||
| Increment in R2 | 0.0458 | 0.0441 | 0.0545 | 0.0626 | ||
|
| ||||||
| Regression coeff. (95% C.I.) | 2.43* (0.2; 4.6) | |||||
| Beta weight | 0.35 | |||||
| Increment in R2 | 0.0316 | |||||
Significance levels: *P < 0.05, **P < 0.01, ***P < 0.001.
aBroad-spectrum antibiotics: second- and third-generation cephalosporins, fluoroquinolones, carbapenems, and penicillins with enzyme inhibitors.
bAll penicillins: penicillinase sensitive, penicillinase resistant and extended-spectrum penicillins.
cDRG: Diagnosis-related groups.